Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol

Brenton J Baguley, Tina L Skinner, Michael D Leveritt, Olivia R L Wright, Brenton J Baguley, Tina L Skinner, Michael D Leveritt, Olivia R L Wright

Abstract

Background: Cancer-related fatigue is one of the most prevalent, prolonged and distressing side effects of prostate cancer treatment with androgen deprivation therapy. Preliminary evidence suggests natural therapies such as nutrition therapy and structured exercise prescription can reduce symptoms of cancer-related fatigue. Men appear to change their habitual dietary patterns after prostate cancer diagnosis, yet prostate-specific dietary guidelines provide limited support for managing adverse side effects of treatment. The exercise literature has shown high intensity interval training can improve various aspects of health that are typically impaired with androgen deprivation therapy; however exercise at this intensity is yet to be conducted in men with prostate cancer. The purpose of this study is to examine the effects of nutrition therapy beyond the current healthy eating guidelines with high intensity interval training for managing cancer-related fatigue in men with prostate cancer treated with androgen deprivation therapy.

Methods/design: This is a two-arm randomized control trial of 116 men with prostate cancer and survivors treated with androgen deprivation therapy. Participants will be randomized to either the intervention group i.e. nutrition therapy and high intensity interval training, or usual care. The intervention group will receive 20 weeks of individualized nutrition therapy from an Accredited Practising Dietitian, and high intensity interval training (from weeks 12-20 of the intervention) from an Accredited Exercise Physiologist. The usual care group will maintain their standard treatment regimen over the 20 weeks. Both groups will undertake primary and secondary outcome testing at baseline, week 8, 12, and 20; testing includes questionnaires of fatigue and quality of life, objective measures of body composition, muscular strength, cardiorespiratory fitness, biomarkers for disease progression, as well as dietary analysis. The primary outcomes for this trial are measures of fatigue and quality of life.

Discussion: This study is the first of its kind to determine the efficacy of nutrition therapy above the healthy eating guidelines and high intensity interval training for alleviating prostate-cancer related fatigue. If successful, nutrition therapy and high intensity interval training may be proposed as an effective therapy for managing cancer-related fatigue and improving quality of life in men during and after prostate cancer treatment.

Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12615000512527 . Trial registered on the 22/5/2015.

Keywords: Cancer related fatigue; Exercise; Nutrition therapy; Prostate cancer.

Figures

Fig. 1
Fig. 1
CONSORT diagram and schematic representation of the study. Legend: Wk = week, HIIT = high intensity interval training
Fig. 2
Fig. 2
Nutrition therapy assessment schematic representation. Legend: DEXA = Dual-energy X-ray absorptiometry, F = fruit, V = vegetable, Sat fat = saturated fat, EER = estimated energy requirement, HIIT = high intensity interval training, Std = standard drink, BMI = body mass index

References

    1. Australian Institute of Health and Welfare Cancer in Australia: actual incidence and mortality data from 1982 to 2007 and projections to 2010. Asia Pac J Clin Oncol. 2011;7(4):325–338. doi: 10.1111/j.1743-7563.2011.01502.x.
    1. Australian Institute of Health and Welfare: Cancer in Australia Actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012. Asia Pac J Clin Oncol. 2013;9:199–213. doi: 10.1111/ajco.12127.
    1. Australian Institute of Health and Welfare Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol. 2013;9(1):29–39. doi: 10.1111/ajco.12062.
    1. Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer. 2013;21(6):1761–1771. doi: 10.1007/s00520-013-1751-5.
    1. Storey DJ, McLaren DB, Atkinson MA, Butcher I, Frew LC, Smyth JF, Sharpe M. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol. 2012;23(6):1542–1549. doi: 10.1093/annonc/mdr447.
    1. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–4456. doi: 10.1200/JCO.2006.06.2497.
    1. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008;28(12):1511–1522. doi: 10.1592/phco.28.12.1511.
    1. Milena B-B, Adrian SD, Denis CM, Michael AC, Majnu J, Josephine E, Shehzad B. Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy. J Clin Oncol. 2006;24(24):3979–3983. doi: 10.1200/JCO.2006.05.9741.
    1. Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol. 2012;35(5):504–509. doi: 10.1097/COC.0b013e318201a406.
    1. Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manag. 2012;43(1):96–110. doi: 10.1016/j.jpainsymman.2011.03.006.
    1. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM. The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. J Cancer Surviv. 2010;4(2):128–139. doi: 10.1007/s11764-009-0114-1.
    1. Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009;12(2):198–203. doi: 10.1038/pcan.2008.51.
    1. Drummond F, Kinnear H, O’Leary E, Donnelly, Gavin A, Sharp L. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;1.
    1. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc. 2006;54(1):85–90. doi: 10.1111/j.1532-5415.2005.00567.x.
    1. Luo HC, Cheng LP, Cheng HH, Fu ZC, Liao SG, Li DS, Zheng WF, Lin GS, Zhu JF, Xu JF, et al. Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation. Med Oncol. 2014;31(6):991. doi: 10.1007/s12032-014-0991-7.
    1. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, et al. Cancer-related fatigue. J Natl Compr Canc Netw. 2010;8(8):904–931.
    1. Wang XS, Zhao F, Fisch MJ, O'Mara AM, Cella D, Mendoza TR, Cleeland CS. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120(3):425–432. doi: 10.1002/cncr.28434.
    1. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, et al. Survivorship: fatigue, version 1.2014. J Natl Compr Canc Netw. 2014;12(6):876–887.
    1. Bourke L, Doll H, Crank H, Daley A, Rosario D, Saxton JM. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study. Cancer Epidemiol Biomark Prev. 2011;20(4):647–657. doi: 10.1158/1055-9965.EPI-10-1143.
    1. Bourke L, Gilbert S, Hooper R, Steed LA, Joshi M, Catto JWF, Saxton JM, Rosario DJ. Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial. Eur Urol. 2014;65(5):865–872. doi: 10.1016/j.eururo.2013.09.040.
    1. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009;27(3):344–351. doi: 10.1200/JCO.2007.15.4963.
    1. Santa Mina D, Alibhai SM, Matthew AG, Guglietti CL, Pirbaglou M, Trachtenberg J, Ritvo P. A randomized trial of aerobic versus resistance exercise in prostate cancer survivors. J Aging Phys Act. 2013;21(4):455–478. doi: 10.1123/japa.21.4.455.
    1. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–2052. doi: 10.1249/01.mss.0000233803.48691.8b.
    1. Culos-Reed SN, Robinson JW, Lau H, Stephenson L, Keats M, Norris S, Kline G, Faris P. Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention. Support Care Cancer. 2010;18(5):591–599. doi: 10.1007/s00520-009-0694-3.
    1. Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, Chambers SK, Newton RU. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: A randomised controlled trial. BJU Int. 2014;115(2):256–66. doi: 10.1111/bju.12646.
    1. Edvardsen E, Skjonsberg OH, Holme I, Nordsletten L, Borchsenius F, Anderssen SA. High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax. 2015;70(3):244–250. doi: 10.1136/thoraxjnl-2014-205944.
    1. Buffart LM, De Backer IC, Schep G, Vreugdenhil A, Brug J, Chinapaw MJ. Fatigue mediates the relationship between physical fitness and quality of life in cancer survivors. J Sci Med Sport. 2013;16(2):99–104. doi: 10.1016/j.jsams.2012.05.014.
    1. Andersen C, Rorth M, Ejlertsen B, Stage M, Moller T, Midtgaard J, Quist M, Bloomquist K, Adamsen L. The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue. Eur J Oncol Nurs. 2013;17(3):331–339. doi: 10.1016/j.ejon.2012.09.003.
    1. Devin JL, Sax AT, Hughes GI, Jenkins DG, Aitken JF, Chambers SK, Dunn JC, Bolam KA, Skinner TL. The influence of high-intensity compared with moderate-intensity exercise training on cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised controlled trial. J Cancer Surviv. 2015;10(3):467–79. doi: 10.1007/s11764-015-0490-7.
    1. Food Standards Agency. Eat well, be well. .
    1. O'Neill RF, Haseen F, Murray LJ, O'Sullivan JM, Cantwell MM. A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer. J Cancer Surviv. 2015;9(3):431–440. doi: 10.1007/s11764-014-0417-8.
    1. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009;24(Suppl 2):S389–S394. doi: 10.1007/s11606-009-0968-y.
    1. Nguyen PL, Alibhai SMH, Basaria S, D’Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. Eur Urol. 2014;67(5):825–36. doi: 10.1016/j.eururo.2014.07.010.
    1. Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 2011;74(3):289–293. doi: 10.1111/j.1365-2265.2010.03939.x.
    1. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62(4):242–274. doi: 10.3322/caac.21142.
    1. Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W, 3rd, Salner AL, Zelefsky MJ, Aragon-Ching JB, Slovin SF, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64(4):225–249. doi: 10.3322/caac.21234.
    1. Dietitians Associaion of Australia. DAA Best Practice Guidlelines for the Treatment of Overweight and Obesity in Adults. Canberra: Dietitians Association of Australia; 2012.
    1. Dietitians Associaion of Australia . Evidence based practice guideliens for the nutritional management of type 2 diabetes mellitus for adults. Canberra: Dietitians Associaion of Australia; 2006.
    1. National Heart Foundation of Australia . Dietary fats and dietary cholesterol for cardiovascular health. Canberra: National Heart Foundation of Australia; 2009.
    1. Ferris-Tortajada J, Berbel-Tornero O, Garcia-Castell J, Ortega-Garcia JA, Lopez-Andreu JA. Dietetic factors associated with prostate cancer: protective effects of Mediterranean diet. Actas Urol Esp. 2012;36(4):239–245. doi: 10.1016/j.acuro.2011.08.002.
    1. Nissensohn M, Roman-Vinas B, Sanchez-Villegas A, Piscopo S, Serra-Majem L. The effect of the mediterranean diet on hypertension: a systematic review and meta-analysis. J Nutr Educ Behav. 2016;48(1):42–53.e41. doi: 10.1016/j.jneb.2015.08.023.
    1. Schwingshackl L, Missbach B, Konig J, Hoffmann G. Adherence to a Mediterranean diet and risk of diabetes: a systematic review and meta-analysis. Public Health Nutr. 2015;18(7):1292–1299. doi: 10.1017/S1368980014001542.
    1. van de Vijver LP, Kardinaal AF, Couet C, Aro A, Kafatos A, Steingrimsdottir L, Amorim Cruz JA, Moreiras O, Becker W, van Amelsvoort JM, et al. Association between trans fatty acid intake and cardiovascular risk factors in Europe: the TRANSFAIR study. Eur J Clin Nutr. 2000;54(2):126–135. doi: 10.1038/sj.ejcn.1600906.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10(1):28–55. doi: 10.1016/j.ijsu.2011.10.001.
    1. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13(2):63–74. doi: 10.1016/S0885-3924(96)00274-6.
    1. Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE. Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales. J Pain Symptom Manag. 2002;24(6):547–561. doi: 10.1016/S0885-3924(02)00529-8.
    1. Jocham HR, Widdershoven GAM, Dassen TWN, Halfens R. Reliability and validity of the EORTC QLQ-C30 in palliative care cancer patients. Cen Eur J Med. 2009;4(3):348–357.
    1. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer. Value Health. 2009;12(1):124–129. doi: 10.1111/j.1524-4733.2008.00409.x.
    1. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44(16):2418–2424. doi: 10.1016/j.ejca.2008.07.030.
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi: 10.1097/00005650-199206000-00002.
    1. Guirado VM, Taricco MA, Nobre MR, Couto EB, Jr, Ribas ES, Meluzzi A, Brock RS, Dias MR, Rodrigues R, Teixeira MJ. Quality of life in adult intradural primary spinal tumors: 36-Item Short Form Health Survey correlation with McCormick and Aminoff-Logue scales. J Neurosurg Spine. 2013;19(6):721–735. doi: 10.3171/2013.8.SPINE12706.
    1. Stewart A, Marfell-Jones M, Olds T, H. DR. International Standards of Anthropometric Assessment. New Zealand: Internation Society for the Advancement of Kinathropometry; 2011.
    1. Stevens PJ, Syddall HE, Patel HP, Martin HJ, Cooper C, Aihie Sayer A. Is grip strength a good marker of physical performance among community-dwelling older people? J Nutr Health Aging. 2012;16(9):769–774. doi: 10.1007/s12603-012-0388-2.
    1. Cornish RS, Bolam KA, Skinner TL. Effect of Caffeine on Exercise Capacity and Function in Prostate Cancer Survivors. Med Sci Sports Exerc. 2015;47(3):468–475. doi: 10.1249/MSS.0000000000000429.
    1. Taaffe DR, Duret C, Wheeler S, Marcus R. Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults. J Am Geriatr Soc. 1999;47(10):1208–1214. doi: 10.1111/j.1532-5415.1999.tb05201.x.
    1. Wasserman K, Hansen J, Sue D, Casaburi R, Whipp B. Principles of exercise testing and interpretiation: including pathophysiology and clinical appliactions. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
    1. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–381. doi: 10.1249/00005768-198205000-00012.
    1. American Association of Cardiovascular Pulmonary Rehabilitation . Guidelines for cardiac rehabilitation and secondary prevention programs. Champaign, IL: Human Kinetics; 2004.
    1. Poole DC, Wilkerson DP, Jones AM. Validity of criteria for establishing maximal O2 uptake during ramp exercise tests. Eur J Appl Physiol. 2008;102(4):403–410. doi: 10.1007/s00421-007-0596-3.
    1. Martin GS. The interviewer-administered, open-ended diet history method for assessing usual dietary intakes in clinical research: relative and criterion validation studies. Woollongong: The University of Woolongong; 2004.
    1. Tapsell LC, Pettengell K, Denmeade SL. Assessment of a narrative approach to the diet history. Public Health Nutr. 1999;2(1):61–67. doi: 10.1017/S1368980099000087.
    1. Williams T. This = that: a life-size photo guide to food serves. Toowong, Qld: Trudy Williams Nutrition & Dietetics; 2011.
    1. Lovibond SH, Lovibond PF. Psychology Foundation of A: Manual for the depression anxiety stress scales. Sydney, N.S.W: Psychology Foundation of Australia; 1995.
    1. Nieuwenhuijsen K, de Boer AGEM, Verbeek JHAM, Blonk RWB, van Dijk FJH. The Depression Anxiety Stress Scales (DASS): detecting anxiety disorder and depression in employees absent from work because of mental health problems. Occup Environ Med. 2003;60(suppl 1):i77–i82. doi: 10.1136/oem.60.suppl_1.i77.
    1. Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601–608.
    1. Kendzierski DKD. Physical Activity Enjoyment Scale: Two validation studies. J Sport Exerc Psychol. 1991;13(1):50–64. doi: 10.1123/jsep.13.1.50.
    1. Latorre Roman PA, Garcia Pinillos F, Navarro Martinez AV, Izquierdo Rus T. Validity and reliability of Physical Activity Enjoyment Scale questionnaire (PACES) in children with asthma. J Asthma. 2014;51(6):633–638. doi: 10.3109/02770903.2014.898773.
    1. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985;10(3):141–146.
    1. Amireault S, Godin G, Lacombe J, Sabiston C. Validation of the Godin-Shephard Leisure-Time Physical Activity Questionnaire classification coding system using accelerometer assessment among breast cancer survivors. J Cancer Surviv. 2015;9(3):532–540. doi: 10.1007/s11764-015-0430-6.
    1. Abel MG, Hannon JC, Sell K, Lillie T, Conlin G, Anderson D. Validation of the Kenz Lifecorder EX and ActiGraph GT1M accelerometers for walking and running in adults. Appl Physiol Nutr Metab. 2008;33(6):1155–1164. doi: 10.1139/h08-103.
    1. Swartz AM, Strath SJ, Bassett DR, Jr, O'Brien WL, King GA, Ainsworth BE. Estimation of energy expenditure using CSA accelerometers at hip and wrist sites. Med Sci Sports Exerc. 2000;32(9):S450–S456. doi: 10.1097/00005768-200009001-00003.
    1. Frankenfield DC, Muth ER, Rowe WA. The Harris-Benedict studies of human basal metabolism: history and limitations. J Am Diet Assoc. 1998;98(4):439–445. doi: 10.1016/S0002-8223(98)00100-X.
    1. Bosetti C, Filomeno M, Riso P, Polesel J, Levi F, Talamini R, Montella M, Negri E, Franceschi S, La Vecchia C. Cruciferous vegetables and cancer risk in a network of case-control studies. Ann Oncol. 2012;23(8):2198–2203. doi: 10.1093/annonc/mdr604.
    1. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev. 2004;13(3):340–345.
    1. Chen J, Song Y, Zhang L. Lycopene/tomato consumption and the risk of prostate cancer: a systematic review and meta-analysis of prospective studies. J Nutr Sci Vitaminol. 2013;59(3):213–223. doi: 10.3177/jnsv.59.213.
    1. Pelser C, Mondul AM, Hollenbeck AR, Park Y. Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2013;22(4):697–707. doi: 10.1158/1055-9965.EPI-12-1196-T.
    1. Lee S-A, Zheng W. Well-Done Meat Intake, Heterocyclic Amine Exposure, and Cancer Risk. Nutr Cancer. 2009;61(4):437–446. doi: 10.1080/01635580802710741.
    1. Mandair D, Rossi RE, Pericleous M, Whyand T, Caplin ME. Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutrition & metabolism. 2014;11:30. doi: 10.1186/1743-7075-11-30.
    1. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS ONE. 2009;4(9):e7038. doi: 10.1371/journal.pone.0007038.
    1. National Health and Medical Research Council. Australian dietary guidelines. Canberra: NHMRC; 2013. Available from: .
    1. American College of Sports Medicine ACSM’s new preparticipation health screening recommendations from ACSM's guidelines for exercise testing and prescription, ninth edition. Curr Sports Med Rep. 2013;12(4):215–217. doi: 10.1249/JSR.0b013e31829a68cf.
    1. Köhler N, Gansera L, Holze S, Friedrich M, Rebmann U, Stolzenburg J-U, Truss M, Fahlenkamp D, Scholz H-J, Brähler E. Cancer-related fatigue in patients before and after radical prostatectomy. Results of a prospective multi-centre study. Support Care Cancer. 2014;22(11):2883–2889. doi: 10.1007/s00520-014-2265-5.
    1. Ornish D, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174(3):1065–1070. doi: 10.1097/01.ju.0000169487.49018.73.
    1. Ornish D, Magbanua MJ, Weidner G, Weinberg V, Kemp C, Green C, Mattie MD, Marlin R, Simko J, Shinohara K, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A. 2008;105(24):8369–8374. doi: 10.1073/pnas.0803080105.
    1. Galvão DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, Lamb DS, Chambers SK, Newton RU. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 radar. Eur Urol. 2014;65(5):856–864. doi: 10.1016/j.eururo.2013.09.041.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel